June 10, 2024 03:24 PM EDT
R&D
Pharma

Paxlovid did not beat place­bo in Stan­ford-led long Covid study

Max Bayer

Pharma Reporter

Pfiz­er’s Covid-19 an­tivi­ral did not im­prove symp­toms in pa­tients with long Covid com­pared to place­bo — the lat­est dis­ap­point­ment for pa­tients with the post-in­fec­tion con­di­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times